Crescendo raises £17.5m series A as Astellas ventures in
This article was originally published in Scrip
Executive Summary
Crescendo Biologics of the UK has raised £17.5m ($28m) in a series A financing led by Imperial Innovations and including new investor Astellas Venture Management (AVM). The UK biotech says the cash will fund its lead program, which is in topical dermatology, through to clinical proof of concept. Founding seed investor Sofinnova Partners also contributed significantly to the round.
You may also be interested in...
Crescendo Raises $70m In Largest European Biotech Series B Of Year
Crescendo Biologics raises $70m to take its first Humabody asset into clinical trials for prostate cancer; the company’s CEO Peter Pack tells Scrip more about its diverse financiers and plans for big pharma partnering in the future.
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.